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Aims
As a response to the economic and financial crisis that
hit Europe and the rest of the world in 2008, most
health authorities adopted series of measures to contain
or to reduce the healthcare expenditure. In 2010-2011,
some 116 health reforms were adopted or planned in
the European Union (EU)/European Economic Area
(EEA). Some measures can potentially severely impact
public health. This analysis explores the impact of such
measures for patients with rare diseases (RD).
Methods
A literature search was done, in addition to the collec-
tion of information from RD patients’ organisations.
Press articles as well as report from international organi-
sations (OECD, EC, WHO) were analysed. Proceedings
from conferences on the impact of the economic crisis
on the health of citizens were used. There are important
limits when analysing measures taken and the impact
we observe: no causal relation can be made.
Results
In many countries, the most frequent measures adopted
to reduce the health consisted in price reduction of
pharmaceuticals (15 price reductions in 11 countries),
change in co-payment (13 measures in 9), reimburse-
ment (8 countries), reference price system (10 countries)
and INN prescribing made mandatory. Other health
budgets were also affected (public health, care…).
Information on the consequences for citizens or
patients is limited: increased incidence of suicides in the
UK, of HIV infection cases in I.V drug users in Greece,
with also an increase of stillbirths. For RD, according to
one survey among 403 Greek patients, those with a RD
were more likely to report a medicine shortage than
patients with a chronic disease (37/96 versus 23/207). In
France, reimbursement of transport to centres of exper-
tise can be refused. In Romania, a list of 101 medicines
for which a reimbursement decision has been postponed
for 5 years includes 21 medicines for RD. In Spain, a list
of 43 medicines that can be obtained at the hospital but
now with co-payment includes 13 products for RD. In
the UK, the fund for new treatments for RD was sup-
pressed. In Germany, the price negotiation for most
orphan medicinal products (OMP) with G-BA lasts for
more than 15 months. A systematic review of articles on
payer assessment for OMP showed that in average 1.4
articles were published by year between 2000 and 2008
and in average 8.8 between 2008 and 2013, indicating
more acute difficulties with OMPs since the onset of the
economic crisis.
Conclusions
Our analysis certainly reveals increased access to care
difficulties, with some indications of moderately severe
issues but no global “catastrophe”. Facts and testimonies
from literature search and patients are few, and the
health impact of the measures can hardly be estimated.
Our next action will consist of a questionnaire sent
directly to patients with RD in Europe to document on
the difficulties they are facing.
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